Tests Songling Xuemaikang Capsules in adults with mild high blood pressure
Tests a herbal capsule against placebo in adults aged 35 to 65 with mild hypertension.
Plain-language title generated from the registry record
Registry title: Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial
Key facts
- Where
- Beijing, Jinan, Jining, Suzhou, and Taiyuan, ChinaSee the 5 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 65 years old?
Source: NCT06093932, who can take part
Where in China
- Xiyuan Hospital of China Academy of Chinese Medical SciencesBeijing, ChinaTaking people
- Affiliated Hospital of Shandong University of Traditional Chinese MedicineJinan, ChinaNot yet recruiting
- China Academy of Chinese Medical Sciences Xiyuan Hospital Jining HospitalJining, ChinaNot yet recruiting
- Suzhou Hosptial of Traditional Chinese MedicineSuzhou, ChinaNot yet recruiting
- China Academy of Chinese Medical Sciences Xiyuan Hospital Shanxi HospitalTaiyuan, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
- Trial code
- NCT06093932
- Record updated
- 20 August 2024
- Original description
The purpose of this study is:Read full original descriptionShow less
Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized, Multicenter, Double-blind, Placebo-controlled Trial
The purpose of this study is:
1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension. 2. To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade 1 hypertension. 3. To explore the underlying mechanisms of the therapeutic effects of SLXMKC on the intervention of grade 1 hypertension.
Inclusion: Age between 35-65 years old, male or female; Grade 1 essential hypertension; Taking no antihypertensive drugs or taking antihypertensive drugs irregularly in the past ; Sign the informed consent.
Exclusion: Hyperlipidemia with or without taking lipid-lowering drugs; Gastrointestinal diseases, which may affect drug absorption; Be allergic to the clinical trial medicine; Combined with other serious primary diseases or malignant tumors; Hypertensive comorbidities (cerebrovascular disease, other cardiovascular diseases, renal disease, peripheral artery disease, retinopathy, diabetes); Other serious conditions in which is not fit for the study; Significant liver and kidney dysfunction, ALT and AST upper the twice of normal range, Scr≥2.0mg/dl, eGFR<60ml/(min·1. 73m2); Pregnant or breastfeeding women, men who plan to give birth within half a year; Combined with left ventricular hypertrophy, ABI < 0.9, CIMT ≥ 0.9mm or atherosclerotic plaque.